These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26720844)

  • 1. Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.
    Dhruva SS; Prasad V
    JAMA Oncol; 2016 Feb; 2(2):165-6. PubMed ID: 26720844
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimizing waste during preparation of blinatumomab infusions.
    Marini BL; Wechter AR; Burke PW; Bixby D; Perissinotti AJ
    Am J Health Syst Pharm; 2016 Jan; 73(2):19-20. PubMed ID: 26721530
    [No Abstract]   [Full Text] [Related]  

  • 3. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How we infuse blinatumomab.
    Oranges K; Windawi S; Powell S; Dallago D; Escobar N; Rheingold SR
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28541. PubMed ID: 32573958
    [No Abstract]   [Full Text] [Related]  

  • 6. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
    Advani AS
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):776-7. PubMed ID: 22252580
    [No Abstract]   [Full Text] [Related]  

  • 7. A Multidisciplinary Approach to Standardizing Processes for Blinatumomab Administration.
    DePadova S; Howlett C; Rivera K
    Clin J Oncol Nurs; 2016 Oct; 20(5):466-9. PubMed ID: 27668365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab in acute lymphoblastic leukemia.
    Thomas X; Lejeune C
    Expert Rev Anticancer Ther; 2016; 16(3):251-3. PubMed ID: 26775917
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursement for oral chemotherapy.
    Bailes JS
    J Natl Compr Canc Netw; 2003 Oct; 1 Suppl 3():S-45-8. PubMed ID: 23570137
    [No Abstract]   [Full Text] [Related]  

  • 11. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
    Keating AK; Gossai N; Phillips CL; Maloney K; Campbell K; Doan A; Bhojwani D; Burke MJ; Verneris MR
    Blood Adv; 2019 Jul; 3(13):1926-1929. PubMed ID: 31243002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing Administration Challenges Associated With Blinatumomab Infusions: A Multidisciplinary Approach.
    Szoch S; Boord C; Duffy A; Patzke C
    J Infus Nurs; 2018; 41(4):241-246. PubMed ID: 29958260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab for Acute Lymphoblastic Leukemia.
    Kantarjian H; Jabbour E; Topp MS
    N Engl J Med; 2017 Jun; 376(23):e49. PubMed ID: 28591537
    [No Abstract]   [Full Text] [Related]  

  • 15. Limits on Medicare's ability to control rising spending on cancer drugs.
    Bach PB
    N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
    [No Abstract]   [Full Text] [Related]  

  • 16. Blinatumomab for the treatment of B-cell lymphoma.
    Oak E; Bartlett NL
    Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab for the treatment of acute lymphoblastic leukemia.
    Kaplan JB; Grischenko M; Giles FJ
    Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia.
    Turner J; Schneider SM
    Clin J Oncol Nurs; 2016 Apr; 20(2):165-8. PubMed ID: 26991709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).
    Friberg G; Reese D
    Ann Oncol; 2017 Aug; 28(8):2009-2012. PubMed ID: 28379283
    [No Abstract]   [Full Text] [Related]  

  • 20. Blinatumomab: first global approval.
    Sanford M
    Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.